JP MORGAN/CALL/ELI LILLY & CO/820/0.01/17.01.25 | Real-time Bid/Ask 09:49:48 2024-07-05 am EDT | ||
| 1.39 EUR / 1.4 EUR | +7.31% |
|
| Current month | -10.34% | ||
| 1 month | +35.42% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-04 | 1.3 | -9.09% |
| 24-07-03 | 1.43 | +7.52% |
| 24-07-02 | 1.33 | -6.34% |
| 24-07-01 | 1.42 | -2.07% |
| 24-06-28 | 1.45 | +3.57% |
Delayed Quote Börse Stuttgart
Last update July 04, 2024 at 04:44 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | J.P. Morgan |
| WKN | JK27V6 |
| ISIN | DE000JK27V68 |
| Date issued | 2024-02-08 |
| Strike | 820 $ |
| Maturity | 2025-01-17 (196 Days) |
| Parity | 100 : 1 |
| Emission price | 0.48 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.45 € |
|---|---|
| Lowest since issue | 0.51 € |
| Spread | 0.01 € |
| Spread % | 0.75% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
898.1
USD
Average target price
870.3
USD
Spread / Average Target
-3.10%
- Stock Market
- Warrants
- Warrant
